Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Borsari

Showing results (591-600 of 618) with videos related to

Pageof 62
Sort By:
Dermatology (Basel, Switzerland)|March 15, 2023
Advanced Cutaneous Squamous Cell Carcinoma: Italian Multicentric Retrospective Analysis of Patient Profiles and Therapeutic ApproachesMaria Mannino, Alfredo Piccerillo, Emi Dika, et al.
Human Molecular Genetics|September 15, 2018
Bi-allelic mutations in MYL1 cause a severe congenital myopathyGianina Ravenscroft, Irina T Zaharieva, Carlo A Bortolotti, et al.
Molecules (Basel, Switzerland)|March 12, 2017
Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic ActivityFlavio Di Pisa, Giacomo Landi, Lucia Dello Iacono, et al.
ACS Medicinal Chemistry Letters|April 19, 2019
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-<i>Trypanosoma brucei</i> AgentChiara Borsari, Nuno Santarem, Sara Macedo, et al.
Critical Care (London, England)|April 30, 2022
Early prolonged prone position in noninvasively ventilated patients with SARS-CoV-2-related moderate-to-severe hypoxemic respiratory failure: clinical outcomes and mechanisms for treatment response in the PRO-NIV studyGiovanni Musso, Claudio Taliano, Federica Molinaro, et al.
European Journal of Medicinal Chemistry|October 15, 2017
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activityElisa Uliassi, Giulia Fiorani, R Luise Krauth-Siegel, et al.
JAMA Internal Medicine|February 17, 2025
Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids: A Randomized Clinical TrialWilliam C Becker, Karen H Seal, David B Nelson, et al.
Molecules (Basel, Switzerland)|July 24, 2021
Design, Synthesis and Antiparasitic Evaluation of Click PhospholipidsGeorge E Magoulas, Pantelis Afroudakis, Kalliopi Georgikopoulou, et al.
Contemporary Clinical Trials|January 24, 2023
Rationale and design of a multisite randomized clinical trial examining an integrated behavioral treatment for veterans with co-occurring chronic pain and opioid use disorder: The pain and opioids integrated treatment in veterans (POSITIVE) trialKevin E Vowles, Katie Witkiewitz, Erik Clarke, et al.
European Journal of Medicinal Chemistry|January 27, 2020
Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaignPasquale Linciano, Gregorio Cullia, Chiara Borsari, et al.
Pageof 62

Showing results (591-600 of 618) with videos related to

Sort By:
Pageof 62
Dermatology (Basel, Switzerland)|March 15, 2023
Advanced Cutaneous Squamous Cell Carcinoma: Italian Multicentric Retrospective Analysis of Patient Profiles and Therapeutic ApproachesMaria Mannino, Alfredo Piccerillo, Emi Dika, et al.
Human Molecular Genetics|September 15, 2018
Bi-allelic mutations in MYL1 cause a severe congenital myopathyGianina Ravenscroft, Irina T Zaharieva, Carlo A Bortolotti, et al.
Molecules (Basel, Switzerland)|March 12, 2017
Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic ActivityFlavio Di Pisa, Giacomo Landi, Lucia Dello Iacono, et al.
ACS Medicinal Chemistry Letters|April 19, 2019
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-<i>Trypanosoma brucei</i> AgentChiara Borsari, Nuno Santarem, Sara Macedo, et al.
Critical Care (London, England)|April 30, 2022
Early prolonged prone position in noninvasively ventilated patients with SARS-CoV-2-related moderate-to-severe hypoxemic respiratory failure: clinical outcomes and mechanisms for treatment response in the PRO-NIV studyGiovanni Musso, Claudio Taliano, Federica Molinaro, et al.
European Journal of Medicinal Chemistry|October 15, 2017
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activityElisa Uliassi, Giulia Fiorani, R Luise Krauth-Siegel, et al.
JAMA Internal Medicine|February 17, 2025
Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids: A Randomized Clinical TrialWilliam C Becker, Karen H Seal, David B Nelson, et al.
Molecules (Basel, Switzerland)|July 24, 2021
Design, Synthesis and Antiparasitic Evaluation of Click PhospholipidsGeorge E Magoulas, Pantelis Afroudakis, Kalliopi Georgikopoulou, et al.
Contemporary Clinical Trials|January 24, 2023
Rationale and design of a multisite randomized clinical trial examining an integrated behavioral treatment for veterans with co-occurring chronic pain and opioid use disorder: The pain and opioids integrated treatment in veterans (POSITIVE) trialKevin E Vowles, Katie Witkiewitz, Erik Clarke, et al.
European Journal of Medicinal Chemistry|January 27, 2020
Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaignPasquale Linciano, Gregorio Cullia, Chiara Borsari, et al.
Pageof 62